Vestibology

Italian survey on benign paroxysmal positional vertigo

Survey italiana sulla vertigine parossistica posizionale

A. MESSINA, A.P. CASANI, M. MANFRIN, G. GUIDETTI

1 Otoneurology and Tinnitus Unit, Chair of Audiology, P. Giaccone University Hospital, Palermo; 2 Department of Surgical, Medical and Critical Care Pathology, University of Pisa; 3 ENT Clinic, IRCCS Policlinico San Matteo, Pavia; 4 Vertigo Center, Poliambulatorio Chirurgico Modenese, Modena

SUMMARY

Benign paroxysmal positional vertigo (BPPV) is the most common type of peripheral vertigo. BPPV often relapses after the first episode, with a recurrence rate between 15% and 50%. To date both the aetiopathogenetic processes that lead to otoconia detachment and the factors that make BPPV a relapsing disease are still unclear, but recent epidemiological studies have shown a possible association with cardiovascular risk factors. The aim of the present study (Sesto Senso Survey) was to evaluate in the Italian population through an observational survey, the main demographic and clinical characteristics of patients with BPPV (first episode or recurrent) with particular focus on the potential cardiovascular risk factors. The survey was conducted in 158 vestibology centres across Italy on 2,682 patients (mean age 59.3 ± 15.0 years; 39.1% males and 60.9% females) suffering from BPPV, from January 2013 to December 2014. The results showed a high prevalence of cardiovascular risk factors such as high blood pressure (55.8%), hypercholesterolaemia (38.6%) and diabetes (17.7%), as well as a family history of cardiovascular disease (49.4%). A high percentage of patients also had hearing loss (42.9%), tinnitus (41.2%), or both (26.8%). The presence of hypertension, dyslipidaemia and pre-existing cardiovascular comorbidities were significantly related to recurrent BPPV episodes (OR range between 1.84 and 2.31). In addition, the association with diabetes and thyroid/autoimmune disease (OR range between 1.73 and 2.31) was relevant. The survey results confirm the significant association between cardiovascular comorbidities and recurrent BPPV and identify them as a potential important risk factor for recurrence of BPPV in the Italian population, paving the way for the evaluation of new therapeutic strategies in the treatment of this disease.

KEY WORDS: Benign paroxysmal positional vertigo • Risk factors • Cardiovascular diseases • Therapy

RIASSUNTO

La vertigine parossistica posizionale benigna (VPPB) è il tipo più comune di vertigine periferica. Frequentemente dopo il primo episodio la VPPB presenta ricorrenze, con un tasso di ricorrenza tra il 15% ed il 50%. Ad oggi non vi è chiarezza sui processi eziopatogenetici che portano al distacco degli otoconi né su quali siano i fattori che rendono la VPPB una patologia recidivante, ma recenti studi epidemiologici hanno evidenziato una possibile associazione con fattori di rischio cardiovascolari. Lo scopo del presente studio (Sesto Senso Survey) è stato quello di valutare nella popolazione italiana, attraverso un’indagine osservazionale, le principali caratteristiche demografiche e cliniche dei pazienti con VPPB (primo episodio o ricorrente), con particolare attenzione ai potenziali fattori di rischio cardiovascolare. L’indagine è stata condotta in 158 centri di Vestibologia in tutta Italia su 2,682 pazienti (età media 59,3 ± 15,0 anni; 39,1 maschi e 60,9% femmine) affetti da VPPB, da gennaio 2013 a dicembre 2014. I risultati hanno mostrato in questi pazienti l’alta prevalenza di fattori di rischio cardiovascolari come ipertensione arteriosa (55,8%), ipercolesterolemia (38,6%) e diabete (17,7%), oltre ad una elevata familiarietà per malattie cardiovascolari (49,4%). In un’elevata percentuale di pazienti si è inoltre registrata la presenza di ipoacusia (42,9%), acufeni (41,2%) o entrambi (26,8%). Significativamente correlata agli episodi di ricidiva di VPPB è risultata la presenza di ipertensione arteriosa, dislipidemia e comorbidità cardiovascolare accertata (range OR tra 1,84 e 2,31). Rilevanti anche le associazioni con diabete e patologie tiroidee e autoimmuni (range OR tra 1,73 e 1,89). I risultati dell’indagine confermano la significativa associazione tra comorbidità cardiovascolari e VPPB ricettivi e le identificano come importante potenziale fattore di rischio per le ricidive di VPPB nella popolazione italiana, aprendo la strada alla valutazione di nuove strategie terapeutiche nel trattamento di questa patologia.

PAROLE CHIAVE: Vertigine parossistica posizionale benigna • Fattori di rischio • Patologie cardiovascolari • Terapia

Acta Otorhinolaryngol Ital 2017;37:328-335
Introduction

Benign paroxysmal positional vertigo (BPPV) is a clinical syndrome characterised by brief recurrent episodes of vertigo, triggered by changes in head position with respect to gravity and due to abnormal stimulation of the cupula of one of the three semicircular canals, most frequently the posterior one. The excitatory response of the cupula is generated by otooliths that detach from the macula of the utricle and move into the lumen of the semicircular canal in response to movements of the head; otooliths then reach the cupula that is stimulated abnormally by the small crystals, thus causing vertigo and nystagmus. Otooliths, which have been observed during surgery, may in some cases adhere to the cupula, generating a form of BPPV called cupulolithiasis 1-2. The characteristic signs of BPPV are evoked when the subject’s head is positioned so that the plane of the semicircular canal is aligned with gravity, generating nystagmus and vertigo. The duration, frequency and intensity of symptoms can vary. Autonomic manifestations (nausea, vomiting) or a persistent residual dizziness can be also present 1-2.

BPPV is the most common type of peripheral vertigo, with a reported prevalence of 11 to 64 cases per 100,000 persons, with a peak in the 50-70 age group; a higher prevalence is reported among women 1-3. BPPV often relapses after the first episode, with a recurrence rate of between 15% and 50%, and the episode usually recurs within a few months 1-4.

To date both the aetiological processes that lead to otoconia detachment and the factors that make BPPV a recurrent disease are unclear. In recent years, various epidemiological studies have analysed family history data in order to highlight any comorbidities that might be related to recurrences of BPPV 1-4. Between 2007 and 2009, the Revert international registry collected data from over 4000 consecutive cases of vertigo observed in 618 vestibology out-patient clinics belonging to the “Sesto Senso Study Group” from January 2013 to December 2014. The inclusion criterion was a diagnosis of BPPV, either initial episode or recurrence. We considered recurrent BPPV the new clinical manifestation of vertigo signs and symptoms after the resolution of the previous episode, diagnosed according to the standard practice of each centre.

The analysis of the association between recurrence and potential cardiovascular risk factors.

Materials and methods

Our investigation is a multicentric observational study. We collected patient history and diagnostic and clinical assessments on 2,682 patients who had referred to 158 Italian vestibology out-patient clinics belonging to the “Sesto Senso Study Group” from January 2013 to December 2014. The inclusion criterion was a diagnosis of BPPV, either initial episode or recurrence. We considered recurrent BPPV the new clinical manifestation of vertigo signs and symptoms after the resolution of the previous episode, diagnosed according to the standard practice of each centre. The data were registered using a form divided into four sections (Fig. 1):

1. Patient history (possible risk factors): family history of vertigo and cardiovascular disease, vascular and metabolic risk factors (hypertension, hypercholesterolemia, hypertriglyceridaemia, acute or chronic cerebrovascular disease, acute or chronic cardiovascular disease, diabetes, hyperuricaemia), use of drugs and/ or other comorbidities.

2. Hearing loss and tinnitus: reported audiological symptoms associated with episodes of BPPV.

3. Characteristics of BPPV, first episode or recurrence: number and frequency of episodes, canal involved.

4. Treatment of first BPPV episode and any subsequent episodes: description of the treatment used; in the event of pharmacological treatment, duration of therapy.

The demographic and clinical data were summarised in frequency tables or central tendency and dispersion tables, using the most suitable indicators for the variables (mean, standard deviation). The discrete data were summarised as absolute frequencies and relative frequency percentages. Missing values were not considered for calculation of the relative frequency percentages.

The analysis of the association between recurrence and possible risk factors was performed through the $\chi^2$ test and the odds ratios (OR) with 95% confidence intervals.
Statistical analysis was performed using SPSS Statistical Package, ver. 16.0.

In the event of missing data, no replacement approach was applied.

Results

Demographic data

A total of 2,682 valid forms were collected for statistical processing (Table I). Most patients were women (60.9%). The mean age at diagnosis was 59.3 years (SD ± 15.0), with a percentage of over 65 of 38.3%. The 60-69 age group was the most frequent (26.6%), while only 0.2% were under 18 years of age.

Medical history and comorbidities

The possible risk factors are shown in Table II. 55.8% of patients had high blood pressure and nearly half (49.4%) had a family history of cardiovascular disease. Hypercholesterolaemia and hypertriglyceridaemia were found, respectively, in 38.6% and 21.1% of patients, and diabetes in 17.7%. At anamnnesis, 12.3% of the sample reported a previous diagnosis of cardiovascular disease and 12.6% a cerebrovascular disease. The frequency of thyroid pa-
Italian survey on benign paroxysmal positional vertigo

Hearing loss and tinnitus

In most cases, BPPV was associated with auditory symptoms (Table II). 42.9% of patients reported hearing loss, 80.3% of whom reported onset before the episode of BPPV and 85.4% of cases were of a sensorineural nature. 41.2% of patients had tinnitus, 69.9% of whom reported onset before the episode of BPPV and in 52.2% of cases this was bilateral. 26.8% of the sample presented hearing loss and tinnitus simultaneously. The patients who had hearing loss were older (p < 0.001). In particular, the average age of the patients with hearing loss (n = 1131) was of 66.4 years (SD 12.4), while the average age of patients without hearing loss (n = 1506) was 53.8 years (SD 14.4).

Characteristics of BPPV

The clinical features of BPPV episodes are shown in Table III. A near-uniform distribution was recorded between the first episode of BPPV (47.5%) and recurrent BPPV (52.5%). In terms of the frequency of recurring episodes, 1-5 episodes per year was the most commonly reported range (84.3%), while 15.7% reported 6 or more episodes per year. The canal most commonly involved in the first episode of BPPV was the posterior semicircular canal (57.4%), and most relapses involved the same canal (49.2%).

Treatment of vertigo

The treatment of BPPV, reported in Table IV, is based on rehabilitative manoeuvres (85.9%), followed by vasoactive drugs (35.9%). Use of antivertigo drugs was found in roughly one-third of the total sample (32.7%). Only in 4.4% of cases were central nervous system (CNS) depressants used.

In most cases, medical treatment lasted between 1 and 2 months (64.7%), while in about one-third of patients (30%) it was 3-6 months and only in 5.3% of cases did treatment continue for over 6 months.

Association between recurrence and comorbidities

In addition to the descriptive research, statistical processing of the data was performed in order to analyse the association between recurrent BPPV and possible risk factors (Table V, Fig. 2). The following significant correlations were found: family history of vertigo associated with cardiovascular disease (OR = 1.5, p < 0.001 and OR = 1.46, p < 0.005), hypertension (OR = 2.05, p < 0.001), hypercholesterolaemia (OR = 1.84, p < 0.001), hypertriglyceridaemia (OR = 2.11, p < 0.001), cerebrovascular disease (OR = 1.88, p < 0.001) and cardiovascular disease (OR = 2.31, p < 0.001). In addition, the association with diabetes was significant (OR = 1.73, p < 0.001). Finally, a correlation with the use of proton-pump inhibitors and
with the use of ototoxic drugs was also found (OR 1.81, p < 0.001 and OR 1.96, p < 0.001, respectively).

**Discussion**

To date it is still unclear what is the aetiopathogenetic mechanism of BPPV and whether there are any other diseases related to the recurrence of BPPV. Recent epidemiological studies have shown a possible association with cardiovascular risk factors. In the present observational study, cardiovascular history was assessed for 2,682 patients diagnosed with BPPV, both...
initial episodes and recurrences, who had referred to 158 Italian vestibology out-patient clinics from January 2013 to December 2014. Most patients were over 40 years old (88.6%), with a prevalence of women (60.9%) and a BPPV recurrence rate of 52.5%, in line with data reported in literature. With regards to the prevalence of recurrent BPPV, only the Ogun et al. survey conducted in the United States has until now registered a higher frequency (76.3%), but this, as reported by the authors, may be due to the survey procedures used which favoured selection of patients with recurrent BPPV.

Our survey showed a high prevalence of cardiovascular risk factors such as high blood pressure (55.8%), hypercholesterolaemia (38.6%) and diabetes (17.7%), as well as family history of cardiovascular disease (49.4%). A comparison of the relative frequencies of these risk factors in the study sample with the data available for the general population highlighted the higher prevalence of these parameters in patients with BPPV vs. the general population (Fig. 3).

A high proportion of patients had hearing loss and/or tinnitus (up to 42.9%), a result consistent with Ogun et al. study in which 41.9% of subjects displayed hearing loss, suggesting that audiological symptoms in BPPV patients are potential markers of vascular pathophysiology in the inner ear that should be validated.

Analysis of correlations also suggests that cardiovascular risk factors expose the BPPV subject to a risk of relapse with OR values that sometimes are higher than 2. Specifically, the presence of arterial hypertension, dyslipidaemia and established cardiovascular comorbidities (OR range between 1.84 and 2.31) would seem to be significantly related to episodes of recurrent BPPV, and association with diabetes and thyroid/autoimmune disease (OR range between 1.42 and 1.89) would seem to be relevant. These results support the hypothesis of a vascular role in

### Table V. Association between the first episode of BPPV or recurrent BPPV and comorbidities, drugs and lifestyles.

|                   | Patients at first episode | Patients with recurrences | Crude OR | CI 95% | p (*) |
|-------------------|--------------------------|---------------------------|----------|--------|-------|
| **Family history**|                          |                           |          |        |       |
| Cardiovascular diseases | 526 (44.1%) | 715 (54.7%) | 1.54 | 1.31-1.80 | < 0.001 |
| Dizziness symptoms | 159 (14.6%) | 239 (20.0%) | 1.46 | 1.17-1.82 | < 0.005 |
| **Risk factors and vascular disorders** | | | | | |
| Hypertension       | 557 (46.9%) | 844 (64.4%) | 2.05 | 1.75-2.41 | < 0.001 |
| Hypercholesterolaemia | 348 (31.2%) | 558 (45.5%) | 1.84 | 1.55-2.18 | < 0.001 |
| Hypertriglyceridaemia | 157 (14.8%) | 314 (26.8%) | 2.11 | 1.70-2.61 | < 0.001 |
| Cerebrovascular disease (acute or chronic) | 96 (9.2%) | 178 (15.9%) | 1.88 | 1.44-2.45 | < 0.001 |
| Cardiovascular disease | 82 (7.9%) | 183 (16.5%) | 2.31 | 1.76-3.05 | < 0.001 |
| **Metabolic disorders** | | | | | |
| Diabetes | 152 (13.6%) | 261 (21.5%) | 1.73 | 1.39-2.16 | < 0.001 |
| Hyperuricaemia | 24 (2.3%) | 47 (4.2%) | 1.86 | 1.13-3.06 | < 0.05 |
| **Drugs** | | | | | |
| Use of proton-pump inhibitors (PPI) | 234 (21.9%) | 396 (33.7%) | 1.81 | 1.5-2.19 | < 0.001 |
| Use of ototoxic drugs | 63 (6.2%) | 124 (11.5%) | 1.96 | 1.43-2.69 | < 0.001 |
| **Other** | | | | | |
| Visual disturbances | 180 (17.9%) | 288 (25.6%) | 1.59 | 1.29-1.96 | < 0.001 |
| Headaches and/or migraine | 279 (27.0%) | 377 (33.1%) | 1.34 | 1.12-1.61 | < 0.01 |
| Cervical hernia | 122 (12.4%) | 187 (17.0%) | 1.44 | 1.13-1.84 | < 0.025 |
| Radiotherapy | 35 (3.6%) | 36 (3.4%) | 0.93 | 0.58-1.45 | ns |
| Smoker | 316 (30.3%) | 338 (29.6%) | 0.97 | 0.81-1.16 | ns |
| Giant cell arteritis | 24 (2.5%) | 13 (1.2%) | 0.49 | 0.25-0.97 | < 0.05 |
| Cryoglobulinaemia | 4 (0.4%) | 4 (0.4%) | 0.92 | 0.23-3.69 | ns |
| Macroglobulinaemia | 8 (0.8%) | 10 (1.0%) | 1.17 | 0.45-2.94 | ns |
| Thyroid disfunction | 118 (11.9%) | 174 (16.1%) | 1.42 | 1.10-1.82 | < 0.025 |
| Autoimmune disease | 35 (3.7%) | 63 (6.0%) | 1.68 | 1.10-2.57 | < 0.05 |
| Inflammatory and/or autoimmune disease (acute or chronic) | 26 (2.8%) | 52 (5.2%) | 1.89 | 1.17-3.04 | < 0.05 |

Crude Odds Ratio (OR) and 95% Confidence Intervals (95%) and their p-values.

*\( \chi^2 \) Test.
the aetiopathogenesis of BPPV and its recurrence. Moreover, the link between inflammation and vascular pathophysiology of the inner ear and audio-vestibular disorders has already been pointed out\(^\text{10-13}\). As is known, the blood supply to the inner ear is a terminal circulation and given the lack of collateral circulation, any even partial occlusion of the AICA (anterior inferior cerebellar artery) or VBA (vertebrobasilar artery) can cause an ischaemic event in the inner ear\(^\text{11}\). Recently, patients with idiopathic sudden hearing loss were shown to have significantly lower flow-mediated dilation of the brachial artery than controls (5.6 ± 1.6 vs. 7.7 ± 3.7; \(p < 0.01\))\(^\text{14}\), significantly lower levels (\(p = 0.018\)) of endothelial progenitor cells\(^\text{15}\) and increased plasma levels of adhesion molecules, which is an early sign of endothelial dysfunction\(^\text{16}\).

The data have also suggested an unexpected correlation between the recurrence of BPPV and use of proton-pump inhibitors, and confirmed a possible correlation between recurrence of BPPV and the use of ototoxic drugs. These data stimulate further specific studies.

Finally, it is interesting to note that in our sample more than 80% of patients reported hearing loss or tinnitus prior to the episode of BPPV. At the same time, it should also be underlined the fact that patients with hearing loss were significantly older. For these reasons, and given the importance of the issue, to evaluate the possible correlation between hearing loss and BPPV it would be necessary in the future perform a specific study, which evaluates in detail the various characteristics of the hearing loss in BPPV for classes of age and comparing such data with an adequate sample of subjects not suffering from BPPV. The survey results also suggests some considerations regarding therapeutic strategies adopted in the treatment of BPPV. Standard treatment generally involves rehabilitation therapy based on liberatory or repositioning manoeuvres needed to achieve resolution that are effective in resolving symptoms in up to 90% of cases within 24 hours\(^\text{17}\). However, the number of manoeuvres needed to achieve resolution can vary and the incidence of residual dizziness after treatment is high (60%) and long-term (13-16 days), thus complicating complete resolution of symptoms\(^\text{18,19}\). The use of vasoactive drugs could therefore be of help, especially to contrast any pathogenetic mechanism with a microcirculatory component. Specifically, treatment could include not only drugs to reduce the impact of known risk factors (antihypertensives, statins, anti-diabetics) but also more specific vascular drugs to counteract “causal” damage generated on the endothelial wall in the inner ear, such as glycosaminoglycans (GAGs), which exert anti-inflammatory and antithrombotic actions on the endothelial wall\(^\text{20-24}\). In this regard, our study showed that antivertigo drugs were prescribed in almost 33% of cases and vasoactive drugs in about 36%, thus demonstrating that specialists are aware of vascular risk factors.

Our study has some limitations. For example, many parameters have not been evaluated, including brain MRI, post-traumatic vertigo and psychiatric disorders. Furthermore, the study did not have an appropriate control of the population without BPPV. Finally, the observational nature of the study, obviously, did not allow definitive answers about the investigated correlations, which require appropriate studies, but that nonetheless gave, albeit partial, a significant picture of the Italian real-life situation on BPPV helping to increase knowledge about the comorbidity in BPPV also investigated recently in other studies\(^\text{25-27}\).

**Conclusions**

In conclusion, the present study investigated the demographic and clinical characteristics of 2,682 Italian patients with BPPV. In particular, the results have highlighted a population of patients with 60 years on average, a prevalence of women (60.9%) and a high BPPV recurrence rate (52.5%). Finally, the study seems to confirm the prevalence of cardiovascular comorbidities in patients suffering from BPPV and identify them as potential important risk factors for recurrent BPPV in the Italian population, paving the way for the evaluation of new therapeutic strategies.

**References**

1. Kim JS, Zee DS. *Benign paroxysmal positional vertigo*. N Engl J Med 2014;370:1138-47.
2. Fife TD, Iverson DJ, Lempert T, et al. *Practice parameter: therapies for benign paroxysmal positional vertigo* (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2008;70:2067-74.
3. Saxena A, Prabhakar MC. *Performance of DHI Score as a predictor of benign paroxysmal positional vertigo in geriatric patients with dizziness/vertigo: a cross-sectional study*. PLoS One 2013;8:e85106.
4. von Brevern M, Radtke A, Lezius F, et al. *Epidemiology of benign paroxysmal positional vertigo: a population based study*. J Neurol Neurosurg Psychiatry 2007;78:710-5.
5. De Stefano A, Dispensa F, Suarez H, et al. *A multicenter observational study on the role of comorbidities in the recurrent episodes of benign paroxysmal positional vertigo*. Auris Nasus Larynx 2014;41:31-6.
Italian survey on benign paroxysmal positional vertigo

6 Ogun OA, Janky KL, Cohn ES, et al. Gender-based comorbidity in benign paroxysmal positional vertigo. PLoS One 2014;9:e105546.

7 Agus S, Benecke H, Thum C, et al. Clinical and demographic features of vertigo: findings from the REVERT Registry. Front Neurol 2013;4:48.

8 Papi G, Guidetti G, Corsello SM, et al. The association between benign paroxysmal positional vertigo and autoimmune chronic thyroiditis is not related to thyroid status. Thyroid 2010;20:237-8.

9 Kao CL, Cheng YY, Leu HB, et al. Increased risk of ischemic stroke in patients with benign paroxysmal positional vertigo: a 9-year follow-up nationwide population study in Taiwan. Front Aging Neurosci 2014;6:108.

10 Guidetti G. La terapia della vertigine vascolare nella pratica ambulatoriale: esperienza multicentrica (VascVert Study). Otorinolaringol 2005;55:237-46.

11 Lee H. Recent advances in acute hearing loss due to posterior circulation ischemic stroke. J Neurol Sci 2014;38:23-9.

12 Trune D. Vascular pathophysiology in hearing disorders. Semin Hear 2012;33:242-50.

13 Faralli M, Ricci G, Molini E, et al. Paroxysmal positional vertigo: the role of age as a prognostic factor. Acta Otorinolaringol Ital 2006;26:25-31.

14 Ciccone MM, Cortese F, Pinto M, et al. Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing loss. Atherosclerosis 2012;225:511-6.

15 Quaranta M, Ramunni A, De Luca C, et al. Endothelial progenitor cells in sudden sensorineural hearing loss. Acta Otorinolaringol 2011;131:347-50.

16 Quaranta M, Ramunni A, Brescia P, et al. Soluble intercellular adhesion molecule 1 and soluble vascular cell adhesion molecule 1 in sudden hearing loss. Otol Neurol 2008;29:470-4.

17 Mandalà M, Santoro GP, Asprella Libonati G, et al. Double-blind randomized trial on short-term efficacy of the Semont maneuver for the treatment of posterior canal benign paroxysmal positional vertigo. J Neurol 2012;259:882-5.

18 Seok JI, Lee HM, Yoo JH, et al. Residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo. J Clin Neurol 2008;4:107-10.

19 Leopardi G, Chiarella G, Serafini G, et al. Paroxysmal positional vertigo: short- and long-term clinical and methodological analyses of 794 patients. Acta Otorhinolaringol Ital 2003;23:155-60.

20 Ferrari G, Agnese A, Cavallero A, et al. Medical and surgical treatments for tinnitus: the efficacy of combined treatment with sulodexide and melatonin. J Neurosurg Sci 2015;59:1-9.

21 Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Dev Ther 2014;8:49-65.

22 Neri G, De Stefano A, Baffa C, et al. Treatment of central and sensorineural tinnitus with orally administered melatonin and sulodexide: personal experience from a randomized controlled study. Acta Otorinolaringol Ital 2009;29:86-91.

23 Panu F, Manca T, Cauli S, et al. Efficacia del trattamento con sulodexide nei pazienti affetti da vertigine di origine vascolare. Otorinolaringol 2008;58:159-64.

24 Tirelli G, Zarcone O, Giacomarra V, et al. La vertigine da causa vascolare. Ipotesi patogenetiche e considerazioni terapeutiche. Otorinolaringol 2001;51:61-8.

25 Babac S, Djeric D, Petrovic-Lazic M, et al. Why do treatment failure and recurrences of benign paroxysmal positional vertigo occur? Otol Neurotol 2014;35:1105-10.

26 Picciotti PM, Lucidi D, De Corso E, et al. Comorbidities and recurrence of benign paroxysmal positional vertigo: personal experience. Int J Audiol 2016;55:279-84.

27 Choi SJ, Lee JB, Lim HJ, et al. Clinical features of recurrent or persistent benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 2012;147:919-24.